Evidence map›Paper›PMID 26633638›Full record

ReviewCurrent opinion in HIV and AIDS2016

Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.

Jessica E Haberer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in HIV and AIDS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Retention of clients in HIV oral pre-exposure prophylaxis care in Engela, Namibia.African journal of primary health care & family medicine · 2025
    Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jessica E HabereraCenter for Global Health, Massachusetts General Hospital bDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Funding

Real World Adherence to HIV PrEP in Serodiscordant African CouplesR01MH098744 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2013 to 2017
$3.0M
NIMH NIH HHS R01 MH098744NIMH NIH HHS R01MH098744
6 · The paper itself

Abstract

purpose of reviewThe review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention. RECENT

findingsPrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies. SUMMARY: PrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.

Indexed as

Medication AdherenceAnti-HIV AgentsChemopreventionClinical Trials as TopicDelivery of Health CareDisease Transmission, InfectiousEmtricitabineHIV InfectionsHumansPre-Exposure ProphylaxisTenofovirTreatment OutcomeAnti-HIV AgentsEmtricitabineTenofovir

Identifiers

PMID26633638
PMCPMC4801217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.